Braveheart Bio priced a large biotech IPO tied to a clinical-stage heart drug, positioning the company to build momentum ahead of key development milestones. The report says the Braveheart Bio offering totaled $382 million, with underwriters exercising an option that pushed the total haul to nearly $440 million. The story notes the lead therapy could compete with a Bristol Myers Squibb blockbuster treatment for a form of cardiomyopathy, making the funding relevant not only for Braveheart’s runway but also for the competitive landscape in cardiac therapeutics. For biotech, the deal also signals continued investor willingness to fund cardiovascular programs when the mechanism and target patient population appear well-defined.